The pTriEx﹤TMSYMBOL>﹤/TMSYMBOL>-1.1 Hygro vector is designed to allow rapid characterization of target genes in multiple expression systems, and to allow rapid selection of stable transfected mammalian cells expressing high levels of target protein. With this vector a single recombinant plasmid can be used to test expression in E. coli, insect and vertebrate cells. Expression in vertebrate cells is mediated by a hybrid promoter composed of the CMV immediate early enhancer fused to the chicken -actin promoter. The drug selection marker is expressed under the control of the EMC virus Cap-Independent Translation Enhancer (CITE) sequence (or IRES), allowing rapid selection of transfected mammalian cells using hygromycin. For expression in insect cells, pTriEx-1.1 Hygro contains flanking baculovirus sequences to permit the generation of recombinant baculoviruses using the BacVector﹤TMSYMBOL>﹤/TMSYMBOL> System. In baculovirus-infected insect cells, expression is driven by the very late p10 promoter. Expression in E. coli is regulated by the tightly controlled T7lac promoter. Expression can be induced in hosts such as NovaBlue by infecting with λCE6, a phage that constitutively expresses T7 RNA polymerase from the λpL and λpI promoters. Alternatively, pTriEx recombinant plasmids can be transferred into a (DE3)pLacI host that allows induction with IPTG.This product is sold for internal research use only. Any commercial use of this product, its components, and/or any derivatives thereof (including but not limited to proteins produced using the product or its components) (together and hereinafter the ′EMD Product′) requires signature of a written commercial use agreement with EMD Millipore Corporation or its successor-in-interest. Commercial use shall include but not be limited to: (1) use of the EMD Product to manufacture products for sale to third parties; (2) use of the EMD Product to provide services, information, or data to third parties in exchange for consideration; (3) use of the EMD Product for therapeutic, diagnostic or prophylactic purposes (including as part of a device, chip, assay or other product); or (4) resale of the EMD Product, whether or not such EMD Product is resold for research use. Nothing contained herein shall be deemed to represent or warrant that additional third party rights are not required for use of the EMD Product. Please direct any questions on these use restrictions to: firstname.lastname@example.org.
NOVAGEN is a registered trademark of Merck KGaA, Darmstadt, Germany
20 µg in Plastic ampoule
Toxicity: Standard Handling (A)